<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02347917</url>
  </required_header>
  <id_info>
    <org_study_id>D8807005</org_study_id>
    <nct_id>NCT02347917</nct_id>
  </id_info>
  <brief_title>A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma</brief_title>
  <official_title>A Phase I/II Clinical Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sumitomo Dainippon Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sumitomo Dainippon Pharma Co., Ltd.</source>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter, phase 1/2 study of BBI608 in combination with pemetrexed
      and cisplatin chemotherapy as a 1st line treatment for Malignant Pleural Mesothelioma (MPM).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase1: Assessment of safety of BBI608 given in combination with Pemetrexed and Cisplatin by reporting the adverse events and serious adverse events.</measure>
    <time_frame>17months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase1: Assessment of dose-limiting toxicities (DLTs).</measure>
    <time_frame>23days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase1: Pharmacokinetics profile of BBI608 when administered with pemetrexed and cisplatin.</measure>
    <time_frame>On day 1 of the first cycle: prior to BBI608 dosing and 2,4,6,8,10,12,24 hours after the first dose, :on day 3 of the first cycle prior to BBI608 dosing,12 and 24 hours after first dose, before pemetrexed dosing, after pemetrexed dosing, before cisplatin</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase2: Progression Free Survival (PFS)</measure>
    <time_frame>17months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase1: Anti-tumor activity</measure>
    <time_frame>17months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase1: Progression Free Survival(PFS)</measure>
    <time_frame>17months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase1: Overall Survival(OS)</measure>
    <time_frame>17months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase2: Overall Survival (OS)</measure>
    <time_frame>17months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase2: Response Rate(RR)</measure>
    <time_frame>17months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase2: Disease Control Rate(DCR)</measure>
    <time_frame>17months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase2: Vital Capacity(VC)</measure>
    <time_frame>17months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase2: Forced vital capacity(FVC)</measure>
    <time_frame>17months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase2: Forced Expiratory Volume in 1st second(FEV1)</measure>
    <time_frame>17months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase2: Safety by reporting the adverse events and serious adverse events.</measure>
    <time_frame>17months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Malignant Pleural Mesothelioma</condition>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>BBI608 puls pemetrexed and cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BBI608</intervention_name>
    <description>480 mg orally twice daily (960 mg total daily dose)</description>
    <arm_group_label>BBI608 puls pemetrexed and cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>500 mg/m2 I.V. infusion on Day 1 of each treatment cycle (except for cycle 1, in which Pemetrexed will be given on Day 3).</description>
    <arm_group_label>BBI608 puls pemetrexed and cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>75 mg/m2 I.V. infusion on Day 1 of each treatment cycle (except for Cycle 1, in which Cisplatin will be given on Day 3).</description>
    <arm_group_label>BBI608 puls pemetrexed and cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Phase 1

        Inclusion Criteria:

          -  Histologically confirmed diagnosis of Malignant Pleural Mesothelioma (MPM) or
             Non-Small Cell Lung Cancer (NSCLC).

          -  Measurable disease as defined by the modified Response Evaluation Criteria in Solid
             Tumors (mRECIST) for MPM or the RECIST 1.1 for NSCLC.

          -  ≥ 20 years of age.

          -  Provision of written informed consent.

          -  For male or female patient of child producing potential: Must agree to use
             contraception or take measures to avoid pregnancy during the study and for 30 days
             after the last protocol treatment dose.

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.

          -  Hemoglobin (Hb) ≥ 9.0 g/dL.

          -  Neutrophils ≥ 1500/μL.

          -  Platelets ≥ 100,000/μL.

          -  Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5-fold the upper limit
             of normal range (ULN) [≤ 5-fold ULN with any liver metastasis].

          -  Total bilirubin ≤ 1.5-fold ULN.

          -  Creatinine clearance (estimated value) ≥ 60 mL/min.

          -  Life expectancy ≥ 3 months.

          -  Females of childbearing potential have a negative urine pregnancy test.

        Phase 2

        Inclusion Criteria:

          -  Histologically confirmed diagnosis of MPM.

          -  Treatment naïve and not indicated for resection.

          -  Measurable disease as defined by the modified RECIST.

          -  ≥ 20 years of age.

          -  Provision of written informed consent.

          -  For male or female patient of child producing potential: Must agree to use
             contraception or take measures to avoid pregnancy during the study and for 30 days
             after the last protocol treatment dose.

          -  ECOG Performance Status of 0 or 1.

          -  Hb ≥ 9.0 g/dL.

          -  Neutrophils ≥ 1500/μL.

          -  Platelets ≥ 100,000/μL.

          -  AST and ALT ≤ 2.5-fold ULN [≤ 5-fold ULN for patients with any liver metastasis].

          -  Total bilirubin ≤ 1.5-fold ULN.

          -  Creatinine clearance (estimated value) &gt; 60 mL/min.

          -  Life expectancy ≥ 3 months.

          -  Females of childbearing potential have a negative urine pregnancy test.

        Both Phase 1 and 2

        Exclusion Criteria:

          -  Prior anti-cancer chemotherapy and radiotherapy.

          -  Prior hormonal therapy, immunotherapy, thermotherapy, operation.

          -  Any brain metastasis requiring treatment or symptomatic.

          -  Active multiple primary cancers.

          -  Crohn's disease, ulcerative colitis, small intestine resection.

          -  Abnormal ECGs.

          -  Prior myocardial infarction.

          -  Current use of antiarrhythmic medication.

          -  Uncontrolled concurrent diseases.

          -  Known severe hypersensitivity to pemetrexed, cisplatin or other drugs containing
             platinum.

          -  Women who are pregnant or breastfeeding.

          -  Received other investigational drugs.

          -  Unable or unwilling to swallow BBI608 capsules daily.

          -  Prior treatment with BBI608.

          -  Ineligible for participation in the study in the opinion of the Investigators.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sumitomo Dainippon Pharma Co. Ltd. Japan</last_name>
    <role>Study Director</role>
    <affiliation>Sumitomo Dainippon Pharma Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2015</study_first_submitted>
  <study_first_submitted_qc>January 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2015</study_first_posted>
  <last_update_submitted>February 1, 2018</last_update_submitted>
  <last_update_submitted_qc>February 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Mesothelioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

